Meta-analysis finds SGLT2 inhibitors reduce cardiac arrest risk in CKD patients
SGLT2 Inhibitors Lower Cardiac Arrest Risk in Kidney Disease
This meta-analysis of 8 RCTs evaluated SGLT2 inhibitors versus placebo in patients with chronic kidney disease. SGLT2i significantly reduced…
A meta-analysis of 8 trials found SGLT2 inhibitors cut cardiac arrest risk by 47% in chronic kidney disease patients, though other arrhythmi…
Meta-analysis shows SGLT2 inhibitors reduce all-cause mortality in heart failure patients
Heart Drug Cuts Death Risk by 14% in Heart Failure Patients
This meta-analysis evaluated SGLT2 inhibitor therapy in patients with heart failure, irrespective of ejection fraction or diabetes status. T…
A heart failure drug originally made for diabetes now shows it can cut death risk by 14% and keep people out of the hospital, and it works f…
SGLT-2 inhibitors reduce heart failure hospitalization and stroke in patients with acute coronary syndrome
SGLT-2 Drugs Cut Stroke Risk After Heart Attack
This meta-analysis evaluated SGLT-2 inhibitors in patients hospitalized for acute coronary syndrome with additional risk factors. The analys…
New research shows that a specific diabetes drug can lower the risk of stroke and heart failure in people recovering from a heart attack.
Network meta-analysis compares glucose-lowering therapies for heart failure with reduced ejection fraction and type 2 diabetes
Sotagliflozin Cuts Heart Failure Risk By Half In High-Risk Patients
This systematic review and network meta-analysis synthesized evidence on three glucose-lowering therapies for patients with coexisting heart…
New drugs for diabetes could also save lives in people with heart failure and lower the need for hospital visits.
Scoping review finds SGLT2 inhibitors show kidney protection in IgA nephropathy
Two major trials show kidney-protective effects for a specific IgA nephropathy group
This scoping review synthesizes evidence on SGLT2 inhibitors in IgA nephropathy.
Two large trials found kidney-protective effects for some IgA nephropathy patients taking SGLT2 inhibitors, while real-world data showed red…
Meta-analysis finds GLP-1RA plus SGLT2i reduces UACR in type 2 diabetes with kidney disease
Combining two diabetes drugs protects kidneys better than using just one alone
This systematic review and meta-analysis of 1974 adults with type 2 diabetes and diabetic kidney disease found that combination therapy with…
Combining two common diabetes drugs offers better kidney protection than taking just one alone for people with type 2 diabetes
Meta-analysis and cohort study suggest association between SGLT2 inhibitors and reduced arrhythmia recurrence
SGLT2 Inhibitors Cut AF Recurrence And Improve Heart Function After Ablation
This meta-analysis and retrospective cohort study examined the association between SGLT2 inhibitors and atrial arrhythmia recurrence after c…
New data shows SGLT2 inhibitors lower the risk of irregular heartbeats returning after surgery while strengthening heart muscle in patients …
Semaglutide linked to lower neuropsychiatric event risk vs other diabetes drugs in observational study
Semaglutide linked to lower neuropsychiatric risk than other diabetes drugs
This observational cohort study analyzed 63,215 patients with baseline neuropsychiatric conditions across a large US federated data platform…
A large observational study suggests semaglutide may be associated with a lower risk of neuropsychiatric conditions compared to other common…
Narrative review supports SGLT-2i use in cardiovascular-kidney-metabolic syndrome
New Treatment Shifts How We Fight Heart, Kidney, and Diabetes Damage
This narrative review summarizes evidence on SGLT-2 inhibitors for patients with stages 2–4 cardiovascular-kidney-metabolic syndrome.
Maria, 58, has type 2 diabetes and high blood pressure.
Meta-analysis of dapagliflozin for renal outcomes in type 2 diabetes and CKD
SGLT2 inhibitors lower kidney failure risk in type 2 diabetes patients
This systematic review and meta-analysis of 10 studies synthesized evidence on dapagliflozin for renal outcomes in patients with type 2 diab…
A review of ten studies shows these drugs reduce kidney failure risk in people with type 2 diabetes and kidney disease.
Systematic review links hypertension, diabetes, and pulmonary inflammation; SGLT2 inhibitors show potential
Why Your Blood Pressure Might Be Hurting Your Lungs
This systematic review of 48 articles explores the interplay between arterial hypertension, diabetes mellitus, and pulmonary inflammation.
High blood pressure and diabetes don't just affect your heart and sugar levels; they team up to harm your lungs.
Jordan guideline review highlights SGLT2 inhibitor access barriers for heart failure patients
Heart Failure Patients Face New Insurance Hurdle for Key Drug
This mixed-methods study and guideline analysis surveyed 312 physicians in Jordan regarding prescribing decisions and insurance authorizatio…
A new study reveals that insurance rules, not medical science, are stopping heart failure patients from getting a proven treatment.